{"schema_version":"secwatch.filing_event.v1","accession":"0001794546-26-000015","form_type":"8-K","ticker":"CARL","cik":"0001794546","company_name":"CARLSMED, INC.","filed_at":"2026-08-05T20:05:16+00:00","discovered_at":"2026-08-05T20:06:03.247124+00:00","generated_at":"2026-08-05T20:06:09.061765+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Carlsmed Q2 revenue $18.9M (+57% YoY); raises FY2026 guidance to $74-78M","bullets":["Revenue $18.9M, up 57% YoY from $12.1M; gross margin 76.8% vs 73.4%.","Net loss ($10.5M) vs ($6.8M) prior year; adjusted EBITDA ($8.6M).","Full-year 2026 revenue guidance raised to $74-78M (prior $72-77M), >50% growth at midpoint.","Trained surgeon users up >60% YoY; aprevo cervical now ~10% of quarterly revenue.","CMS IPPS final rule includes new MS-DRG codes for inpatient aprevo lumbar, effective Oct 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001794546-26-000015","json":"https://secwatch.observer/filing/0001794546-26-000015.json","markdown":"https://secwatch.observer/filing/0001794546-26-000015.md","text":"https://secwatch.observer/filing/0001794546-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1794546/000179454626000015/0001794546-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1794546/000179454626000015/carl-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:06:09.061765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}